|
 |
|||
|
|||
 |
|||
 |
 |
|||
Company News
|
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
South San Francisco, CA, 09 July 2008
- Portola Pharmaceuticals, Inc., a privately-held biotechnology company focused on the discovery and development of novel therapeutics for cardiovascular and inflammatory diseases, announced today that is has raised $60 million in a preferred stock financing. Proceeds will be used primarily to advance Portola's two lead antithrombotic clinical candidates, betrixaban and PRT060128, which the company is developing as best-in-class compounds to replace existing standards of care. In addition, funds will be used to develop the company's pre-clinical pipeline including its novel Factor Xa inhibitor antidote, which has the potential to expand the use of anticoagulants. New investors, including D.E. Shaw group, Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and PAC-LINK BioVentures, joined the company's existing investors to complete the round.
top
Abingworth appoints David Mayer
London, UK and Boston, MA, USA, 29 April 2008
top
Abingworth wins European Venture Firm of the Year Award
London, UK, 03 March 2008
top
Abingworth wins European Venture Capital Journal Award
VC House of the Year – Life Sciences
London, UK, 31 January 2008
top
|
Archive:
|
|||||||||||||||||||||||||
